Atorvaliq Suspension
Product Images NDC 46287-030

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Atorvaliq (NDC 46287-030). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cmp Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Effect Of Atorvastatin 10 mg/day On Cumulative Incidence Of Non-fatal Myocardial Infarction Or Coronary Heart Disease Death (in Ascot-lla) (Image 02)

This appears to be a graph showing the cumulative incidence of something over time, possibly a medical study or clinical trial. There are percentages listed on the y-axis and years on the x-axis. The values on the y-axis start at 15 and go up to 40. There is also a line labeled "HR-084" with a value of 25 at the 5-year mark. A p-value of 0.0005 is listed.*

FDA Label Image

Effect Of Atorvastatin 10 mg/day On Time To Occurrence Of Major Cardiovascular Event (myocardial Infarction, Acute Chd Death, Unstable Angina, Coronary Revascularization, Or Stroke) In Cards (Image 03)

FDA Label Image

Effect Of Atorvastatin 80 mg/day Vs. 10 mg/day On Time To Occurrence Of Major Cardiovascular Events (tnt) (Image 04)

The text is a table showing the percentage of subjects who experienced an event for two different medications: Aorvastatin 10 mg and Aorvastatin 80 mg. It also includes an HR (hazard ratio) value and the p-value for the comparison between the two medications. The table also shows the time to the first major cardiovascular endpoint in years.*

FDA Label Image

Chemical Structure (Spl 01)

FDA Label Image

Principal Display Panel (10 mg Tablet Bottle Label)

Recommended dosage information for Atorvastatin (calcium equivalent to 4mg per mL) oral suspension is available in the Praseribing Information. The oral suspension comes in a 150mL bottle and should be stored at controlled room temperature. The suspension must be shaken well before use and should be consumed within 60 days of opening. Dispensing to patients should be done in the original packaging. This text also includes lot number and expiration date information but due to errors, some characters are not readable.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.